Biotech Daily

Monday August 31, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: MICRO-X UP 8%; ARTRYA DOWN 11%**

*** BLS REVENUE UP 161% TO RECORD $74m; PROFIT UP 214% TO $15m**

*** ADHERIS REVENUE DOWN 46% TO $34m; LOSS DOWN 93% TO $4m**

*** MICROBA REVENUE DOWN 6% TO $15m; LOSS UP 39% TO $21m**

*** IMMUTEP $14.5m REVENUE FROM DR REDDY'S LICENCE**

*** ORTHOCELL REVENUE UP 45% TO $11m; LOSS UP 62% TO $14m**

*** CURVEBEAM REVENUE DOWN 28% TO $9m; LOSS UP 12% TO $19m**

*** ATOMO REVENUE UP 41% TO $5m; LOSS DOWN 29% TO $3.5m**

*** CLEVER CULTURE REVENUE DOWN 15% TO $4.6m; PROFIT TO $2m LOSS**

*** AUDEARA REVENUE UP 17.5% TO $4.5m; LOSS DOWN 27% TO $1.3m**

*** VITASORA REVENUE UP 39% TO $4.3m LOSS DOWN 1% TO $10.6m**

*** BIOINTELECT $10.5m FOR 6 INFECTIOUS DISEASE COMPANIES**

*** ALTERITY $4.2m MST FINANCIAL OPTIONS UNDERWRITING**

*** PERCHERON RECEIVES $700k FEDERAL R&D TAX INCENTIVE**

*** TETRATHERIX SHIPS 1st COMMERCIAL TETRAMATRIX TO US**

*** EMVISION RECRUITS 2/3 OF 'EMU' BRAIN SCANNER TRIAL**

*** AVECHO STARTS 2nd PHASE III TPM-CBD INSOMNIA COHORT**

*** CERETAS TO BEGIN PHASE II ALZHEIMER'S ULTRASOUND TRIAL**

*** ISLAND: MARBURG NATURAL HISTORY STUDY FOR FDA FILINGS**

*** HYDRIX PROGRESSES DEFENCE DEVELOPMENT**

*** GOODBYE UNIVERSAL BIOSENSORS**

*** PINNACLE BELOW 5% OF COCHLEAR**

*** FMR (FIDELITY) REDUCES TO 9% OF SALUDA**

*** MIKE AICHER REPLACES GENETIC SIGNATURES CAROLINE WALDRON**

MARKET REPORT

The Australian stock market fell 0.18 percent on Monday August 31, 2026, with the ASX200 down 16.3 points to 9,076.0 points. Eleven of the Biotech Daily Top 40 companies were up, 22 fell and seven traded unchanged.

Micro-X was the best, up 0.2 cents or 8.0 percent to 2.7 cents, with 96,406 shares traded. Paradigm was up 7.1 percent; Cyclopharm climbed 6.8 percent; Lumos was up 5.0 percent; Nova Eye and Resonance were up more than three percent; Emvision rose 2.4 percent; Dimerix, Nanosonics and Orthocell were up more than one percent; with Resmed and Starpharma up by less than one percent.

Artrya led the falls, down 51 cents or 10.7 percent to $4.24, with 1.4 million shares traded. Clarity lost 9.2 percent; 4D Medical and Artrya were down six percent or more; Clinuvel fell 5.3 percent; Botanix, Immutep and Mesoblast were down four percent or more; Neuren, Optiscan, Polynovo, Proteomics and Saluda lost more than three percent; Actinogen, Compumedics and Imugene shed two percent or more; Aroa, Avita, Cochlear, Imricor, Prescient, Pro Medicus and Telix were down more than one percent; with CSL and Racura down by less than one percent.

BLS PHARMACEUTICALS (FORMERLY BIOXYNE)

BLS says record revenue for the year to June 30, 2026 was up 160.9 percent to $74,164,632, with net profit after tax up 214.15 percent to $15,396,856.
BLS said revenue was from marijuana production contracts through its Breathe Life Sciences business, sales of its marijuana, psilocybin and 3,4-methylene-dioxy-methamphetamine-based (MDMA) products and probiotic Lactobacillus fermentum.
The company said increased revenue reflected “higher manufacturing volumes, broader customer and product activity and continued commercial execution” with higher sales “achieved in all categories [including marijuana] flower, pastilles, vapes and oils … in Australia, [the] UK and Germany”.
Earlier this year, the then Bioxyne said investors overwhelmingly approved its change of name to ‘BLS Pharmaceuticals’ and a 10-to-one consolidation (BD: Jun 22, 2026).
In 2023, the company said it acquired Gold Coast, Queensland’s Breathe Life Sciences for 1,230,000,000 shares (BD: May 22, 2023)
Today, BLS said it expected revenue for the year to June 30, 2027 to be between $105 million and $115 million, or a 42 percent to 55 percent increase on the current year.
The company said the increase was expected to be underpinned by “continued demand in Australia … execution of existing international contracts … [and] a favorable and evolving global regulatory environment, with increasing political and regulatory acceptance of cannabis, MDMA and psilocybin-based medicines”.
BLS managing-director Sam Watson said that in 2025-’26 the company showed “that our strategy is commercially tangible and significant”.
“We enter 2026-’27 with more manufacturing capacity, better market access, bigger contracts and more opportunities than ever before,” Mr Watson said. “Our focus in 2026-’27 is on execution and delivering sustained, long-term value for our shareholders.”
BLS said diluted earnings per share rose 191.3 percent to 6.7 cents, net tangible assets per share rose 146.3 percent to a post-consolidation 13.3 cents and it had cash and equivalents of $13,289,017 at June 30, 2026, compared to $7,667,522 at June 30, 2025.
BLS was up 14 cents or 15.2 percent to $1.06 with 1.4 million shares traded.

ADHERIS HEALTH (FORMERLY MEDADVISOR)

Adheris says revenue for the year to June 30, 2026 fell 46.1 percent to $33,958,311, with net loss after tax down 92.8 percent to $4,309,303.

Last year, the then Medadvisor said adherence software revenue for the year to June 30, 2025 was $62,994,989, with a $60,208,977 loss, compared to revenue of $122,105,767 and a $792,133 maiden profit in the year to June 30, 2024 (BD: Aug 29, 2025).

At that time, the company said it sold its Australia and New Zealand business to Jonas Software and recorded it as discontinued operations for 2024-'25 (BD: Jul 7, 2025).

Today, Adheris said the revenue decline "reflected … lower vaccine program volumes driven by the continued decline in US vaccination rates, lower customer renewal rates … lower average deal sizes as pharmaceutical manufacturer budgets remained constrained, softness across the retail pharmacy network, and internal operational issues".

The company said it had a profit on the sale of its Australia and New Zealand operations, a 37 percent fall in operating expenses to $31.3 million "driven by a 40 percent reduction in employee costs", 25 percent lower contractor costs and control of spending.

Adheris said diluted loss per share fell 93.6 percent, with net tangible assets per share of 0.17 cents in the prior period turned to negative 0.38 cents and it had cash and equivalents of $9,529,557 at June 30, 2026 compared to $10,303,813 in the prior year.

Adheris was unchanged at 1.4 cents.

MICROBA LIFE SCIENCES

Microba says revenue for the year to June 30, 2026 fell 5.8 percent to $14,758,461, with net loss after tax up 38.7 percent to $20,721,356.

Microba said revenue was from sales of its Microbiome Explorer for gut microbiome testing and Metapanel for gastro-intestinal pathogen testing, with the reduction "entirely attributable to the planned phase-out of discontinued legacy products".

The company said core testing revenue was up 92 percent to $8.6 million, with volumes up 78 percent to 22,418 tests; and its loss "affected by non-cash and non-recurring items" including a $4,470,000 gain on derecognition of contingent consideration, a $1,760,000 foreign currency gain in the prior year, a $1,510,000 foreign currency loss, a $750,000 impairment, and a $360,000 gain on liabilities.

The company said diluted loss per share rose 3.6 percent to 3.45 cents, net tangible assets per share fell 88.5 percent to 0.18 cents; and it had cash and equivalents of $7,947,457 at June 30, 2026 compared to $11,740,910 at June 30, 2025.

Microba fell 0.1 cents or 1.8 percent to 5.4 cents with 454,119 shares traded.

IMMUTEP

Immutep says it has $14,556,923 in revenue for the year to June 30, 2026, "mainly attributable to … the licencing and collaboration partner Dr Reddy's".

Last year, Immutep said that Dr Reddy's licenced its eftilagimod alfa, or efti, for up-to $558.6 million, with $US20 million ($A30.2 million) up-front (BD: Dec 9, 2025).

Today, the company said net loss after tax was up 29.1 percent to $79,304,563, with a $30.5 million increase in research and development and intellectual property expenses "mainly due to increases in clinical trial costs".

Immutep said diluted loss per share rose 27.7 percent to 5.39 cents, net tangible asset backing per share fell 55.9 percent to 4.1 cents; and it had cash and cash equivalents of $63,672,558 at June 30, 2026 compared to $67,408,215 at June 30, 2025.

Immutep fell 0.2 cents or four percent to 4.8 cents with 5.8 million shares traded.

ORTHOCELL

Orthocell says revenue for the year to June 30, 2026 was up 45.4 percent to $11,407,156, with net loss after tax up 62.4 percent to $13,914,694.
Last year, Orthocell said revenue for the year to June 30, 2025 from sales of its Striate+ dental bone regeneration and Remplir peripheral nerve repair devices rose 36.4 percent to $9,226,963 (BD: Aug 29, 2025).
Today, the company said revenue for the year to June 30, 2025 was $7,846,788, with certain items previously presented within revenue and other revenue reclassified “to more appropriately reflect their nature” including $1,300,904 reclassified from other revenue to finance income and $60,000 reclassified to grant income.
Orthocell said that its administration and expenses rose 126.1 percent to $9.5 million, sales and marketing costs were up 61.75 percent to $8.5 million, share-based payments were up 145.9 percent to $3.0 million, with research and development expenditure down 33.1 percent to $4.0 million.
The company said diluted loss per share rose 39.5 percent to 5.8 cents, with net tangible assets per share up 122.5 percent to 12.35 cents and it had cash and cash equivalents of $9,452,893 compared to $28,619,929 at June 30, 2025.
Orthocell was up one cent or 1.3 percent to 76.5 cents.

CURVEBEAM A.I.

Curvebeam says revenue for the year to June 30, 2026 fell 28.4 percent to $8,666,146, with net loss after tax up 11.8 percent to $18,831,356.
Curvebeam said sales of its weight-bearing computed tomography devices fell 30.8 percent to $6,155,905, with warranty services revenue up 14.95 percent to $2,156,140 and “other operating revenue” down 73.4 percent to $354,101.
The company said its increased loss was “attributable to …[a] net decrease in gross margin of $2,621,000 due to decrease in revenue of $3,430,000 … alongside additional $640,000 of warranty and obsolescence provisions in current period”.
Curvebeam said it had increased consulting fees, travel expenditure and product registration costs; a fall in its research and development tax incentive, offset by a decrease in staff costs following a restructure, and further staff cuts this year.
The company said diluted loss per share fell 6.7 percent to 4.19 cents, with negative net tangible assets per share up 92.9 percent to negative 1.62 cents; and it had cash and equivalents of $1,636,418 at June 30, 2026, compared to $5,041,148 last year.
Curvebeam was unchanged at 1.8 cents.

ATOMO DIAGNOSTICS

Atomo says revenue for the year to June 30, 2026 was up 40.65 percent to $5,333,849, with net loss after tax down 29.3 percent to $3,513,587.
Atomo said revenue comprised HIV point-of-care test sales of $2,840,399, other point-of-care test sales of $2,150,773 and $342,677 from development fees and other revenue.
The company said revenue margin reduced from 51 percent to 35 percent, “driven mainly by one-off licence fees received in the comparative period”.
Atomo said it had “continued reduction in overhead expenditure for the group”.
The company said diluted loss per share fell 44.7 percent to 0.425 cents, with net tangible assets per share unchanged at 72 cents, and it had cash and equivalents of $3,708,792 at June 30, 2026 compared to $3,219,646 at June 30, 2025.
Atomo was unchanged at 1.8 cents.

CLEVER CULTURE SYSTEMS (FORMERLY LBT INNOVATIONS)

Clever Culture says revenue for the year to June 30, 2026 fell 15.4 percent to $4,619,000, with last year's $1,684,000 net profit after tax turned to a $2,238,000 loss.

Clever Culture said revenue included $2,890,000 from the sale of its automated plate assessment system (Apas) Independence for microbiology analysis, with $1,230,000 from licence, maintenance and support fees, $500,000 in instrument accessory sales and $50,000 in other income.

The company said that its profit turned to a loss due to $1,000,000 in government grants supporting contact plate development being recognized in the prior year, as well as a $610,000 reduction in revenue net of cost of goods sold, maintenance and marketing costs, $1,150,000 in additional staff costs and a $360,000 rise in development expenses.

Clever Culture said last year's 0.079 cent diluted earnings per share was turned to a diluted loss per share of 0.109 cents, with net tangible assets per share down 12.5 percent to 0.14 cents.

The company said it had cash and cash equivalents of $1,697,000 at June 30, 2026 compared to $1,265,000 at June 30, 2025.

Clever Culture was unchanged at 1.6 cents with 1.4 million shares traded.

AUDEARA

Audeara says revenue for the year to June 30, 2026 was up 17.5 percent to $4,449,000, with net loss after tax down 27.1 percent to $1,303,000.

Audeara said revenue was from sales of its hearing-health technologies including hardware, wholesale clinical distribution, white-label product development, engineering services and software licencing.

The company said it "recorded positive net operating cash flow in two consecutive [three-month periods] during the year before the timing of project expenditure, inventory payments and customer receipts affected the full-year result".

Audeara said that its diluted loss per share fell 33.9 percent to 0.72 cents, with net tangible asset backing per share down 89.85 percent to 0.07 cents.

The company said that it had cash and cash equivalents of 739,750 at June 30, 2026 compared to $1,421,091 at June 30, 2025.

Audeara fell half a cent or 15.6 percent to 2.7 cents with 1.1 million shares traded.

VITASORA HEALTH (FORMERLY RESPIRI)

Vitasora says revenue for the year to June 30, 2026 was up 38.6 percent to $4,287,299, with net loss after tax down 0.9 percent to $10,610,137.

Vitasora said that revenue came from sales and licencing of its Vcare remote patient monitoring software.

The company said that its loss reflected continued investment in platform development, patient growth initiatives and operational capability, as well as the improvement being a result of increased revenues and continued focus on operational efficiencies.

The company said that its diluted loss per share fell 24.7 percent to 0.58 cents, with net tangible assets down 54.5 percent to 0.05 cents.

Vitasora said that it had cash and cash equivalents of $3,057,334 at June 30, 2026 compared to $394,240 at June 30, 2025.

Vitasora was up 0.1 cents or 6.7 percent to 1.6 cents.

BIOINTELECT

Biointelect says it will provide $10.48 million to six Australian companies working on infectious disease projects in its inaugural 'Venturer' program funding round.
Biointelect said it was an incubator established through a $32.9 million Medical Research Future Fund grant from the Federal Government and that the funding would provide "research teams [with] the ability to advance their early-stage breakthroughs to commercial and investment readiness".
The organization said the projects would join its incubation program for up-to two years and receive non-dilutive funding, commercialization support, mentoring and access to networks to help secure commercial interest and funding.
Biointelect said funding recipients included Ena Respiratory for its INNA-051 nasal spray for respiratory viruses, Sammvax for its Trivax Group A Streptococcus vaccine and Saccharide Therapeutics for its ST101 malaria vaccine.
The organization said other recipients included Ebivanta Therapeutics for its messenger (m)RNA Epstein-Barr virus vaccine, Proboxis Biotechnology for Japanese encephalitis vaccine production and Adaptivax for adaptable virus-like particle vaccine technology.
Biointelect said it would support two cohorts and "a dedicated top-up round for high-potential projects as part of the program".
The organization said it was "helping to build local capability in translational research and commercialization and supporting the development and growth of Australian … companies developing health technologies across the infectious disease sector".
Biointelect said it received 48 expressions of interest for the first funding round, with expressions of interests opening for the second round on September 21, 2026.
For more information go to: https://www.biointelect.com/biointelect-venturer/.
Biointelect chief executive officer Leah Goodman said the 'Venturer' program used the company's "deep expertise in development and commercialization strategy, regulatory pathways, market access and global partnering to support innovators to progress from promising science toward investment-ready ventures".
"By combining targeted funding with practical, hands-on support and access to national and international networks, Biointelect Venturer is helping strengthen Australia's capability to translate infectious disease innovations into products with real public health impact," Ms Goodman said.

ALTERITY THERAPEUTICS

Alterity says it has a $4.2 million agreement with Sydney's MST Financial Services Pty Ltd to underwrite the exercise of up-to 8,400,000 options.
Alterity said MST Financial Services was appointed the sole underwriter to the offer, with the proceeds to fund the development of ATH434 in multiple system atrophy.
The company said it had 15,918,235 post-consolidation options on issue, exercisable at a post-consolidation 50 cents each by August 31, 2026 (BD: Jun 4, 2026).
Alterity fell 1.5 cents or 2.9 percent to a post-consolidation 50.5 cents.

PERCHERON THERAPEUTICS

Percheron says it has received $700,000 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.
Percheron said the incentive related to expenditure in Australia and overseas for the year to June 30, 2026, with the funds to be used for HMBD-002.
Percheron was untraded at 0.5 cents.

TETRATHERIX

Tetratherix says it has shipped first commercial Tetramatrix polymer to the US, “marking the beginning of product revenue generation”.
Tetratherix said the shipment was being exported to US partner Superpower Health under an exclusive licence and supply agreement for the develop of STEPP-based intra-nasal delivery products for US consumers.
Earlier this year, the company said it had a 10-year, $US3 million a year deal to licence its Tetramatrix “platform polymer” to Superpower Health Inc (BD: Mar 16, 2026).
At the time, Tetratherix said Superpower would research and develop its synthetic thermo-responsive enabling polymer platform, or Stepp, Tetramatrix platform polymer for the “nasal delivery of longevity and metabolic compounds such as [glucagon-like peptide1] GLP-1”, including Ozempic and Wegovy, peptides and hormones.
Today, the company said the first shipment would allow a trial period to finalize the operational supply process and begin data collection.
Tetratherix managing-director Will Knox said the first commercial dispatch was a “significant proof point for Tetratherix, it demonstrates that we can take Tetramatrix from validated science through to commercial-grade product in the hands of a US partner”.
Tetratherix was up 22 cents or 3.2 percent to $7.15.

EMVISION MEDICAL DEVICES

Emvision says it has recruited more than 200 patients in the 300-patient, pivotal validation trial of its ‘Emu’, point-of-care, portable brain scanner for stroke.
Earlier this year, Emvision said it was preparing to include acute ischaemia detection to the 300-patient, pivotal validation trial of its ‘Emu’ brain scanner (BD: May 11, 2026).
Today, the company said recruitment was “supported by trial ramp-up initiatives, protocol enhancements and expanded hours of coverage at participating sites”.
Emvision said additional US academic medical centres were in the process of being added to the trial, expanding recruitment capacity and engagement with the US stroke community ahead of planned commercialization.
The company said it expected full trial enrolment in “early 2027”.
Emvision managing-director Scott Kirkland said that recruiting 200 patients was “an important milestone that demonstrates our recruitment initiatives are contributing to enrolment acceleration”.
Emvision was up four cents or 2.4 percent to $1.71.

AVECHO BIOTECHNOLOGY

Avecho says it has begun recruiting the 320-patient, second and final stage of its 519-participant, phase III trial of TPM cannabidiol (CBD) soft-gel capsule for insomnia.
Earlier this year, Avecho was up as much as 80 percent following data monitoring board approval to continue the up-to 519-patient, phase III trial (BD: Jun 24, 2026).
Today, the company said beginning the second and final patient cohort followed the “successful interim analysis”.
Avecho said about 320 additional participants would be enrolled in the second cohort so that 519 participants completed the study as originally targeted, with sufficient additional participants to replace any who withdrew during the trial.
The company said the final number would be confirmed as recruitment progressed at its existing clinical site network, with additional sites opening to support enrolment.
Avecho was unchanged at 2.3 cents with 10.3 million shares traded.

CERETAS

Ceretas says it has human research ethics committee approval for a 66-patient, phase II trial of Alzheimer's disease ultrasound therapy at Sydney's St Vincent's Hospital.

Earlier this month, the University of Queensland spin-out Ceretas climbed as much as 132 percent on its July 23, $8 million initial public offer (IPO) at 25 cents a share for its portable ultrasound Alzheimer's disease therapy (BD: Aug 3, 2026).

Today, the company said that the randomized, double-blind, sham-controlled, phase II trial had a primary endpoint of a change in overall neuro-psychiatric symptom burden from baseline to week six and secondary endpoints of caregiver distress, durability of treatment effect and overall safety and tolerability at 12 weeks.

Ceretas said St Vincent's Hospital Sydney would begin governance and start-up activities, with the approval covering Newcastle's John Hunter Medical Research Institute, which would proceed through the same process.

The company said it expected "to add further Australian sites in the coming months as additional governance approvals are received".

Ceretas said the first clinical site, Western Sydney's Cognivus Research, had completed governance and was progressing start-up activities, with a site initiation visit completed in mid-August.

Ceretas managing-director Dr Rachel de las Heras said the additional approval was "an important milestone for the … clinical trial".

"With Cognivus site initiation also now complete, we're on the cusp of enrolling our first patients, a defining moment for Ceretas and for patients with Alzheimer's disease living with [behavioral and psychological symptoms of dementia]," Dr de las Heras said.

Ceretas was up nine cents or 10 percent to 99 cents.

ISLAND PHARMACEUTICALS

Island says it has a letter of authorization to cross-reference a detailed non-human primate natural history study of Marburg-Angola virus in US regulatory submissions.

Island said the authorization was "an important regulatory milestone" for the development of galidesivir as a potential medical counter-measure for Marburg virus disease under the US Food and Drug Administration's Animal Rule pathway.

Last year, the company said it completed its acquisition of the Durham, North Carolina-based Biocryst Pharmaceuticals' galidesivir anti-viral program (BD: Jul 31, 2025).

Earlier this year, Island said the FDA confirmed the validity of the proposed Animal Rule regulatory approval pathway for galidesivir in Marburg virus, allowing it to conduct studies in non-human primates (BD: Feb 4, 2026).

Today, the company said natural history data was "an integral part of this regulatory framework and the evidence package required to support a potential new drug application", with the studies characterizing the progression of disease in the absence of treatment, establishing the underlying disease model and baseline against which the efficacy of a therapeutic candidate was assessed.

Island said the authorization allowed it to use "established and detailed body of Marburg focused natural history work rather than independently re-creating an equivalent program".

The company said it would "direct its resources towards generating the galidesivir-specific efficacy, dose-response, treatment-timing and pharmaco-kinetic data required to further advance the program, while providing an important regulatory foundation against which those results can be assessed".

Island was unchanged at 44 cents.

HYDRIX

Hydrix says it is progressing the development and identification of intellectual property with commercial potential in Australian and allied defence.
Hydrix said opportunities were “being prioritized against defence requirements, technology readiness and their potential contribution to Australian sovereign capability”.
The company said it had begun development and feasibility testing of sensing technologies with multiple use cases, including potential unmanned aerial system (UAS), counter-UAS and persistent intelligence, surveillance and reconnaissance applications.
Hydrix said early prototypes were being developed and tested as it assessed technical performance, market requirements and pathways to commercialization.
The company said it was “engaging with universities and research organizations to identify world-class technologies with commercial potential, including opportunities in sensing and edge [artificial intelligence]”.
Previously, Hydrix executive chair Gavin Coote told Biotech Daily: “We’ve been doing defence projects for more than a decade, but they are less than 15 percent of revenue.”
“We are definitely remaining focused on medical technologies, with cardiac and advanced interventional surgical robotics, the two largest client sub-sectors,” Mr Coote said.
Hydrix was unchanged at 0.35 cents with two million shares traded.

UNIVERSAL BIOSENSORS INC

The ASX says Universal Biosensors has been removed from the Official List, effective from August 28, 2026, under Listing Rul 17.15 for not paying its annual listing fees.
Last year, Universal Biosensors Pty Ltd (UBS), a wholly-owned subsidiary of the ASX-listed Universal Biosensors Inc, appointed KPMG as voluntary administrators of UBS; and at the time, Universal Biosensors Inc said it was “urgently considering its options with regards to other companies in the group” (BD: Aug 20, 2025).
Later, the ASX said it suspended Universal Biosensors under Listing Rule 17.3, not at the entity’s request, as it considered the company’s financial conditions was “not adequate to warrant the continued quotation of its securities” (BD: Aug 22, 2025).
Universal Biosensors last traded at 1.4 cents.

COCHLEAR

Brisbane’s Pinnacle Investment Management Group says it has ceased its substantial shareholding in Cochlear.
Pinnacle said that on August 25, 2026 it bought 4,251 shares for $584,271, or $137.44 a share, and sold 49,579 shares for $6,819,408, or $137.55 a share.
Last week, Pinnacle said it held 3,297,233 Cochlear shares (5.04%) and according to its most recent notice, Cochlear had 65,397,075 shares on issue, implying that Pinnacle retained 4.97 percent of the company (BD: Aug 28, 2026).
Cochlear fell $2.18 or 1.6 percent to $133.92 with 11.0 million shares traded.

SALUDA MEDICAL

Fidelity Management and Research (FMR) says it has reduced its substantial shareholding in Saluda from 2,588,987 shares (10.27%) to 2,332,199 shares (9.25%).
The Wilmington, Delaware-based FMR said that it sold shares between July 13 and August 26, 2026 at prices ranging from 39.11 cents a share to 63.76 cents a share.
Saluda fell 1.5 cents or 3.1 percent to 46.5 cents.

GENETIC SIGNATURES

Genetic Signatures says Caroline Waldron has resigned as chair and a director, effective from today, with executive director Mike Aicher to assume the role of chair.

Genetic Signatures said that during Ms Waldron's tenure as chair it had "undertaken a comprehensive reset of its operating model and cost base, strengthened its footprint in [Europe, the Middle East and Africa], provided a clearly defined strategy for sustainable growth and refreshed its board and executive leadership".

The company said Ms Waldron's decision reflected "her desire to devote greater time to her other professional commitments".

Genetic Signatures said it was "currently considering its composition in order to support the company's next phase of development and will make appropriate announcements in due course".

Last week, the company said that following a review it was in discussions with Microba to assess a potential merger to establish "a leading, scalable, ASX-listed infectious disease diagnostics group" (BD: Aug 26, 2026).

At that time, Bcal said it increased its holding in Genetic Signatures to 41,923,644 shares (18.46%) and that it saw the company "as a highly complementary molecular diagnostics company ... [and the] strategic rationale for this investment is to broaden and diversify Bcal's diagnostic platform into infectious diseases, leveraging complementary technical capabilities and laboratory facilities, as well as expanded distribution opportunities".

Genetic Signatures was up 1.5 cents or 18.75 percent to 9.5 cents with 1.9 million shares traded.